MAGE-6 encodes HLA-DRβ1*0401-presented Epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma

Clinical Cancer Research

Volumn 9, Issue 3, 2003, Pages 947-954

  Tatsumi, Tomohide ^a   Kierstead, Lisa S ^a   Ranieri, Elena ^a,b   Gesualdo, Loreto ^b   Schena, Francesco P ^b   Finke, James H ^c   Bukowski, Ronald M ^c   Brusic, Vladimir ^d   Sidney, John ^e   Sette, Alessandro ^e   Logan, Theodore F ^f   Kasamon, Yvette L ^a   Slingluff Jr , Craig L ^g   Kirkwood, John M ^a,h   Storkus, Walter J ^a,h  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BARI   (Italy)

^c LERNER RESEARCH INSTITUTE   (United States)

^d INSTITUTE FOR INFOCOMM RESEARCH   (Singapore)

^e Epimmune   (United States)

^f INDIANA UNIVERSITY   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

^h UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; HLA DR4 ANTIGEN; MAGE 6 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALGORITHM; AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LYMPHOCYTE FUNCTION; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; TUMOR IMMUNITY;

ADENOVIRIDAE; ADULT; AGED; ALGORITHMS; AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; INHIBITORY CONCENTRATION 50; INTERFERON TYPE II; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDES; POLYMERASE CHAIN REACTION; PROTEIN BINDING; TRANSFECTION;

EID: 0037341162     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Imai, Y., Shichijo, S., Yamada, A., Katayama, T., Yano, H., and Itoh, K. Sequence analysis of the MAGE gene family encoding human tumor-rejection antigens. Gene (Amst.), 160: 287-290, 1995.
2. Itoh, K., Hayashi, A., Nakao, M., Hoshino, T., Seki, N., and Shichijo, S. Human tumor rejection antigens MAGE. J. Biochem. (Tokyo), 119: 385-390, 1996.
3. Gibbs, P., Hutchins, A. M., Dorian, K. T., Vaughan, H. A., Davis, I. D., Silvapulie, M., and Cebon, J. S. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Melanoma Res., 10: 259-264, 2000.
4. Zambon, A., Mandruzzato, S., Parenti, A., Macino, B., Dalerba, P., Ruol, A., Merigliano, S., Zaninotto, G., and Zanovello, P. MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer (Phila.), 91: 1882-1888, 2001.
5. Hasagawa, H., Mori, M., Haraguchi, M., Ueo, H., Sugimachi, K., and Akiyoshi, T. Expression spectrum of melanoma antigen-encoding gene family members in colorectal carcinoma. Arch. Pathol. Lab. Med., 122: 551-554, 1998.
6. Ishida, H., Matsumura, T., Salgaller, M. L., Ohmizono, Y., Kadono, Y., and Sawada, T. MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumors. Int. J. Cancer, 69: 375-380, 1996.
7. Sudo, T., Kuramoto, T., Komiya, S., Inoue, A., and Itoh, K. Expression of MAGE genes in osteosarcoma. J. Orthop. Res., 15: 128-132, 1997.
8. Jager, D., Jager, E., and Knuth, A. Vaccination for malignant melanoma: recent developments. Oncology, 60: 1-7, 2001.
9. Weber, J. Melanoma peptide vaccines: from preclinical background to clinical trials. Curr. Oncol. Rep., 2: 38-47, 2000.
10. Rivoltini, L., Loftus, D. J., Squarcina, P., Castelli, C., Rini, F., Arienti, F., Belli, F., Marincola, F. M., Geisler, C., Borsatti, A., Appella, E., and Parmiani, G. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. Crit. Rev. Immunol., 18: 55-63, 1998.
11. Brasanac, D., Markovic-Lipokovski, J., Hadzi-Djokic, J., Muller, G. A., and Muller, C. A. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation of clinical and histopathological data. Neoplasma, 46: 173-178, 1999.
12. Taramelli, D., Fossati, G., Mazzocchi, A., Delia, D., Ferrone, S., and Parmiani, G. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res., 46: 433-439, 1986.
13. Ruiter, D. J., Mattijssen, V., Broecker, E. B., and Ferrone, S. MHC antigens in human melanomas. Semin. Cancer Biol., 2: 35-45, 1991.
14. Hoffmann, T. K., Meidenbauer, N., Muller-Berghaus, J., Storkus, W. J., and Whiteside, T. L. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J. Immunother., 24: 162-171, 2001.
15. Lowes, M. A., Bishop, G. A., Crotty, K., Barnetson, R. S., and Halliday, G. M. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanoma. J. Investig. Dermatol., 108: 914-919, 1997.
16. Schwaab, T., Heaney, J. A., Schned, A. R., Harris, R. D., Cole, B. F., Noelle, R. J., Phillips, D. M., Stempkowski, L., and Ernstoff, M. S. A randomized Phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon α2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol., 163: 1322-1327, 2000.
17. Turvy, D. N., and Blum, J. S. Detection of biotinylated cell surface receptors and MHC molecules in a capture ELISA: a rapid assay to measure endocytosis. J. Immunol. Methods, 212: 9-18, 1998.
18. 51-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells. Proc. Natl. Acad. Sci. USA, 97: 400-405, 2000.
19. Kierstead, L. S., Ranieri, E., Brusic, V., Sidney, J., Sette, A., Slingluff, C. L., Jr., Kirkwood, J. M., and Storkus, W. J. Multiple gp100- and tyrosinase-derived peptides are recognized by melanomareactive CD4+ Th1-type T cells. Br. J. Cancer, 85: 1738-1745, 2001.
20. Honeyman, M. C., Brusic, V., Stone, N. L., and Harrison, L. C. Neural network-based predictions of candidate T-cell epitopes. Nat. Biotechnol., 16: 966-969, 1998.
21. Southwood, S., Sidney, J., Kondo, A., Del Guercio, M-F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., and Sette, A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol., 160: 3363-3383, 1998.
22. Tueting, T., Wilson, C. C., Martin, D. M., Kazamon, Y., Rowles, J., Ma, D. I., Slingluff, C. L., Jr., Wagner, S. N., van der Bruggen, P., Baar, J., Lotze, M. T., and Storkus, W. J. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-γ. J. Immunol., 160: 1139-1147, 1998.
23. Herr, W., Ranieri, E., Olson, W., Zarour, H., Gesualdo, L., and Storkus, W. J. Mature dendritic cells pulsed with tumor freeze-thaw lysate define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses. Blood, 96: 1857-1864, 2000.
24. Herr, W., Ranieri, E., Gambotto, A., Kierstead, L. S., Amoscato, A. A., Gesualdo, L., and Storkus, W. J. Identification of naturally-processed HLA-presented Epstein-Barr virus peptides recognized by ex vivo CD4+ or CD8+ T lymphocytes from human blood. Proc. Natl. Acad. Sci. USA, 96: 12033-12038, 1999.
25. Manici, S., Sturniolo, T., Imro, M. A., Hammer, J., Sinigaglia, F., Noppen, C., Spagnoli, G., Mazzi, B., Bellone, M., Dellabona, P., and Protti, M. P. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med., 189: 871-876, 1999.
26. Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A. M., Boon, T., and van der Bruggen, P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med., 189: 767-778, 1999.
27. Kobayashi, H., Song, Y., Hoon, D. S., Appella, E., and Celis, E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res., 61: 4773-4778, 2001.
28. Skipper, J. C., Hendrickson, R. C., Gulden, P. H., Brichard, V., Van Pel, A., Chen, Y., Shabinowitz, J., Wolfel, T., Slingluff, C. L., Jr., Boon, T., Hunt, D. F., and Engelhard, V. H. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J. Exp. Med., 183: 527-534, 1996.
29. Gjertson, D. W, and S. H. Lee. HLA 1998. In: D. W. Gjertson and P. I. Terasaki (eds.), UCLA Tissue Typing Laboratory, Los Angeles, CA. Am. Soc. Histocompatibility and Immunogenetics, p. 450. 1998.
30. Ranieri, E., Herr, W., Gambotto, A., Olson, W., Robbins, P. D., Salvucci-Kierstead, L., Waykins, S. C., Gesualdo, L., and Storkus, W. J. Dendritic cells transduced with an adenoviral vector encoding the Epstein-Barr Virus latent membrane protein 2B: a new modality for vaccination. J. Virol., 73: 10416-10425, 1999.